---
title: "Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges"
description: "Abbott's Q4 sales rose 4.4% but fell short of analyst expectations, with adjusted EPS meeting forecasts at $1.50. The diagnostics unit faced challenges, leading to a 2.5% sales decline. The company an"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273373469.md"
published_at: "2026-01-22T12:40:50.000Z"
---

# Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges

> Abbott's Q4 sales rose 4.4% but fell short of analyst expectations, with adjusted EPS meeting forecasts at $1.50. The diagnostics unit faced challenges, leading to a 2.5% sales decline. The company announced plans to acquire Exact Sciences, expected to close in Q2 2026, and projects 2026 organic sales growth of 6.5% to 7.5%. The average analyst rating remains "buy," with a 12-month price target of $145.00, reflecting a 20.1% upside from its recent trading price of $120.73.

)

Overview

-   Healthcare co’s Q4 adjusted EPS grew 12%, meeting analyst expectations
-   Q4 sales increased 4.4% reported, 3.0% organic, excluding COVID-19 test sales, but misses analyst expectations
-   Company announced acquisition of Exact Sciences, closing expected in Q2 2026

Outlook

-   Abbott projects full-year 2026 organic sales growth of 6.5% to 7.5%
-   Abbott expects full-year 2026 adjusted EPS of $5.55 to $5.80
-   Company plans new product launches in Nutrition to boost volume growth

Result Drivers

-   MEDICAL DEVICES GROWTH - Sales in Medical Devices increased 12.3% reported, led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management
-   DIAGNOSTICS CHALLENGES - Diagnostics sales decreased 2.5% reported, impacted by lower COVID-19 test sales, though Core Laboratory Diagnostics grew 5.3%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Meet $1.50 $1.50

Adjusted (23

EPS Analysts

)

Q4 Total Miss $11.46 $11.80

revenue billion billion

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 21 “strong buy” or “buy”, 10 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy”
-   Wall Street’s median 12-month price target for Abbott Laboratories is $145.00, about 20.1% above its January 21 closing price of $120.73
-   The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [EXAS.US - Exact Sciences](https://longbridge.com/en/quote/EXAS.US.md)
- [ABT.US - Abbott Laboratories](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 關鍵事實：精密科學計劃在 2026 年第二季度與雅培合併；預計 2025 年收入增長 18% | 精密科學公司正在與雅培合併，預計將在 2026 年第二季度完成，待批准。該公司還結束了與 Freenome Holdings 交易的等待期。精密科學公司在 2025 年的收入增長了 18%，達到 32.5 億美元。篩查收入增長了 26%，達 | [Link](https://longbridge.com/en/news/275986686.md) |
| Xactly 發佈 2026 年銷售補償狀況報告：企業轉向 “支付確定性” 和經驗豐富的人才 | Xactly 發佈了 2026 年銷售薪酬狀態報告，揭示了由於生產力期望上升和市場波動，銷售薪酬策略發生了顯著變化。公司正在減少新任客户經理的薪酬，同時增加經驗豐富員工的收入，導致薪酬差距擴大。報告強調了優先考慮經過驗證的收入生產者的趨勢， | [Link](https://longbridge.com/en/news/275614806.md) |
| 精密科學｜8-K：2025 財年 Q4 營收 8.78 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275944363.md) |
| 精密科學在即將與雅培合併之際面臨着日益增加的運營風險和戰略限制 | 精密科學公司（Exact Sciences Corp，股票代碼：EXAS）由於與雅培（Abbott）即將進行的合併，面臨着增加的運營風險和戰略限制。圍繞該交易的不確定性可能會妨礙公司吸引和留住關鍵人員的能力，從而影響與客户和供應商的關係，這 | [Link](https://longbridge.com/en/news/275996969.md) |
| 在雅培提出 105 美元報價後，是否是時候重新評估精密科學（EXAS）？ | 精密科學（Exact Sciences，股票代碼：EXAS）目前的交易價格為 103.24 美元，過去一年回報率為 109.4%。分析師建議，根據折現現金流（DCF）分析，該股票被低估了 32%，估計每股內在價值為 151.75 美元。市銷 | [Link](https://longbridge.com/en/news/275956793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.